Microsoft to buy aQuantive for $6B

Share this article:
Microsoft agreed to buy digital marketing firm aQuantive in a deal valued at $6 billion.

AQuantive serves as parent company of digital marketing services provider Atlas, online ad space buyer DrivePM and Avenue A | Razorfish, an ad agency whose healthcare client roster includes AstraZeneca, Wyeth and Boston Scientific.

“We’re very excited about the Microsoft deal and the impact it will have on our business,” Avenue A | Razorfish EVP, product development Brad Aronson told MM&M. “Of course, we're as committed as ever to our current clients and look forward to the additional resources we’ll be able to leverage on their behalf.”

The aQuantive deal marks Microsoft’s biggest-ever acquisition as the software firm strives to keep pace with Google in the online ad market. In April, Google agreed to purchase aQuantive rival DoubleClick for $3.1 billion.

The aQuantive/Microsoft deal is the latest in a string of Web ad agency acquisition deals since the beginning of 2007.

In May, WPP Group agreed to buy digital marketing agency 24/7 Real Media.
In April, Yahoo! agreed to buy Right Media.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...